Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes

Neuroscience

Volumn 150, Issue 3, 2007, Pages 585-591

  Lapchak, P A ^a,b,c   Maher, P ^d   Schubert, D ^d   Zivin, J A ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

12 15 LOX inhibitor; anti inflammatory; antioxidant; free radical; matrix metalloproteinase inhibitor; neuroprotection

Indexed keywords

BAICALEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL SURVIVAL; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; IN VITRO STUDY; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RABBIT; SCORING SYSTEM;

ANIMALS; ANTIOXIDANTS; ARACHIDONATE 12-LIPOXYGENASE; ARACHIDONATE 15-LIPOXYGENASE; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVANONES; INTRACRANIAL EMBOLISM; MALE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RABBITS; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 36749068009     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2007.09.033     Document Type: Article

References (41)

1. Aronowski J., Strong R., Shirzadi A., and Grotta J.C. Ethanol plus caffeine (caffeinol) for treatment of ischemic stroke: preclinical experience. Stroke 34 (2003) 1246-1251
2. Bousova I., Martin J., Jahodar L., Dusek J., Palicka V., and Drsata J. Evaluation of in vitro effects of natural substances of plant origin using a model of protein glycoxidation. J Pharm Biomed Anal 37 (2005) 957-962
3. Broderick J.P., Lu M., Kothari R., Levine S.R., Lyden P.D., Haley E.C., Brott T.G., Grotta J., Tilley B.C., Marler J.R., and Frankel M. Finding the most powerful measures of the effectiveness of tissue plasminogen activator in the NINDS tPA stroke trial. Stroke 31 (2000) 2335-2341
4. Buttke T.M., McCubrey J.A., and Owen T.C. Use of an aqueous soluble tetrazolium/formazan assay to measure viability and proliferation of lymphokine-dependent cell lines. J Immunol Methods 157 (1993) 233-240
5. Christou I., Alexandrov A.V., Burgin W.S., Wojner A.W., Felberg R.A., Malkoff M., and Grotta J.C. Timing of recanalization after tissue plasminogen activator therapy determined by transcranial Doppler correlates with clinical recovery from ischemic stroke. Stroke 31 (2000) 1812-1816
6. Grotta J.C., Burgin W.S., El-Mitwalli A., Long M., Campbell M., Morgenstern L.B., Malkoff M., and Alexandrov A.V. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 58 (2001) 2009-2013
7. Hanneken A., Lin F.F., Johnson J., and Maher P. Flavonoids protect human retinal pigment epithelial cells from oxidative-stress-induced death. Invest Ophthalmol Vis Sci 47 (2006) 3164-3177
8. Huang W.H., Lee A.R., Chien P.Y., and Chou T.C. Synthesis of baicalein derivatives as potential anti-aggregatory and anti-inflammatory agents. J Pharm Pharmacol 57 (2005) 219-225
9. Huang Y., Tsang S.Y., Yao X., and Chen Z.Y. Biological properties of baicalein in cardiovascular system. Curr Drug Targets Cardiovasc Haematol Disord 5 (2005) 177-184
10. Lapchak P.A. 3alpha-OL-5-beta-pregnan-20-one hemisuccinate, a steroidal low-affinity NMDA receptor antagonist improves clinical rating scores in a rabbit multiple infarct ischemia model: synergism with tissue plasminogen activator. Exp Neurol 197 (2006) 531-537
11. Lapchak P.A. Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res 1088 (2006) 141-147
12. Lapchak P.A. The phenylpropanoid micronutrient chlorogenic acid improves clinical rating scores in rabbits following multiple infarct ischemic strokes: Synergism with tissue plasminogen activator. Exp Neurol 205 (2007) 407-413
13. Lapchak P.A., and Araujo D.M. Advances in ischemic stroke treatment: neuroprotective and combination therapies. Expert Opin Emerg Drugs 12 (2007) 97-112
14. Lapchak P.A., Araujo D.M., Song D., Wei J., Purdy R., and Zivin J.A. Effects of the spin trap agent disodium-[tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit large clot embolic stroke model: combination studies with tissue plasminogen activator. Stroke 33 (2002) 1665-1670
15. Lapchak P.A., Araujo D.M., Song D., Wei J., and Zivin J.A. Neuroprotective effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) in a rabbit small clot embolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 33 (2002) 1411-1415
16. Lapchak P.A., Araujo D.M., and Zivin J.A. Comparison of tenecteplase with alteplase on clinical rating scores following small clot embolic strokes in rabbits. Exp Neurol 185 (2004) 154-159
17. Lapchak P.A., Song D., Wei J., and Zivin J.A. Coadministration of NXY-059 and tenecteplase six hours following embolic strokes in rabbits improves clinical rating scores. Exp Neurol 188 (2004) 279-285
18. Lapchak P.A., Wei J., and Zivin J.A. Transcranial infrared laser therapy improves clinical rating scores after embolic strokes in rabbits. Stroke 35 (2004) 1985-1988
19. Lapchak P.A., Chapman D.F., and Zivin J.A. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator. Stroke 32 (2001) 147-153
20. Lapchak P.A., and Zivin J.A. Ebselen, a seleno-organic antioxidant, is neuroprotective after emoblic strokes in rabbits: Synergism with low dose tissue plasminogen activator. Stroke 34 (2003) 2013-2018
21. Li Y., Maher P., and Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. Neuron 19 (1997) 453-463
22. Li Y., Maher P., and Schubert D. Phosphatidylcholine-specific phospholipase C regulates glutamate-induced nerve cell death. Proc Natl Acad Sci U S A 95 (1998) 7748-7753
23. Lundbeck (2007) Desmoteplase shows no difference to placebo in trial. http://wwwbeursnl/nieuws/artikelphp?id=224360&taal=US.
24. Ma Z., Otsuyama K., Liu S., Abroun S., Ishikawa H., Tsuyama N., Obata M., Li F.J., Zheng X., Maki Y., Miyamoto K., and Kawano M.M. Baicalein, a component of Scutellaria radix from Huang-Lian-Jie-Du-Tang (HLJDT), leads to suppression of proliferation and induction of apoptosis in human myeloma cells. Blood 105 (2005) 3312-3318
25. Rego A.C., Areias F.M., Santos M.S., and Oliveira C.R. Distinct glycolysis inhibitors determine retinal cell sensitivity to glutamate-mediated injury. Neurochem Res 24 (1999) 351-358
26. Renovis. NXY-059 does not meet efficacy endpoints in phase III trial for acute ischemic stroke. http://wwwmedicalnewstodaycom/medicalnewsphp?newsid=55212.
27. Roy M.K., Nakahara K., Na T.V., Trakoontivakorn G., Takenaka M., Isobe S., and Tsushida T. Baicalein, a flavonoid extracted from a methanolic extract of Oroxylum indicum inhibits proliferation of a cancer cell line in vitro via induction of apoptosis. Pharmazie 62 (2007) 149-153
28. Sigalov E., Fridkin M., Brenneman D.E., and Gozes I. VIP-Related protection against lodoacetate toxicity in pheochromocytoma (PC12) cells: a model for ischemic/hypoxic injury. J Mol Neurosci 15 (2000) 147-154
29. Sperling O., Bromberg Y., Oelsner H., and Zoref-Shani E. Reactive oxygen species play an important role in iodoacetate-induced neurotoxicity in primary rat neuronal cultures and in differentiated PC12 cells. Neurosci Lett 351 (2003) 137-140
30. Tan S., Sagara Y., Liu Y., Maher P., and Schubert D. The regulation of reactive oxygen species production during programmed cell death. J Cell Biol 141 (1998) 1423-1432
31. Tanahashi N., and Fukuuchi Y. Treatment of acute ischemic stroke: recent progress. Intern Med 41 (2002) 337-344
32. van Leyen K., Kim H.Y., Lee S.R., Jin G., Arai K., and Lo E.H. Baicalein and 12/15-lipoxygenase in the ischemic brain. Stroke 37 (2006) 3014-3018
33. Waud D.R. On biological assays involving quantal responses. J Pharmacol Exp Theory 183 (1972) 577-607
34. Zhang L., Zhang Z.G., Liu X., Hozeska A., Stagliano N., Riordan W., Lu M., and Chopp M. Treatment of embolic stroke in rats with bortezomib and recombinant human tissue plasminogen activator. Thromb Haemost 95 (2006) 166-173
35. Zhang L., Zhang Z.G., Zhang R.L., Lu M., Adams J., Elliott P.J., and Chopp M. Postischemic (6-hour) treatment with recombinant human tissue plasminogen activator and proteasome inhibitor PS-519 reduces infarction in a rat model of embolic focal cerebral ischemia. Stroke 32 (2001) 2926-2931
36. Zhang L., Zhang Z.G., Zhang R.L., Lu M., Krams M., and Chopp M. Effects of a selective CD11b/CD18 antagonist and recombinant human tissue plasminogen activator treatment alone and in combination in a rat embolic model of stroke. Stroke 34 (2003) 1790-1795
37. Zhang R.L., Zhang Z.G., and Chopp M. Increased therapeutic efficacy with rt-PA and anti-CD18 antibody treatment of stroke in the rat. Neurology 52 (1999) 273-279
38. Zhao X., Liu S.J., Zhang J., Strong R., Aronowski J., and Grotta J.C. Combining insulin-like growth factor derivatives plus caffeinol produces robust neuroprotection after stroke in rats. Stroke 36 (2005) 129-134
39. Zivin J.A., and Grotta J.C. Animal stroke models. They are relevant to human disease. Stroke 21 (1990) 981-983
40. Zivin J.A., Lyden P.D., DeGirolami U., Kochhar A., Mazzarella V., Hemenway C.C., and Johnston P. Tissue plasminogen activator. Reduction of neurologic damage after experimental embolic stroke. Arch Neurol 45 (1988) 387-391
41. Zivin J.A., and Waud D.R. Quantal bioassay and stroke. Stroke 23 (1992) 767-773